PL375414A1 - Terapeutyczne połączenie inhibitorów kinazy erb Bi terapii przeciwnowotworowych - Google Patents

Terapeutyczne połączenie inhibitorów kinazy erb Bi terapii przeciwnowotworowych

Info

Publication number
PL375414A1
PL375414A1 PL03375414A PL37541403A PL375414A1 PL 375414 A1 PL375414 A1 PL 375414A1 PL 03375414 A PL03375414 A PL 03375414A PL 37541403 A PL37541403 A PL 37541403A PL 375414 A1 PL375414 A1 PL 375414A1
Authority
PL
Poland
Prior art keywords
erb
kinase inhibitors
therapeutic combinations
antineoplastic therapies
antineoplastic
Prior art date
Application number
PL03375414A
Other languages
English (en)
Inventor
William Leon Elliott
David William Fry
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of PL375414A1 publication Critical patent/PL375414A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL03375414A 2002-08-07 2003-07-28 Terapeutyczne połączenie inhibitorów kinazy erb Bi terapii przeciwnowotworowych PL375414A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40170502P 2002-08-07 2002-08-07
US46224703P 2003-04-11 2003-04-11

Publications (1)

Publication Number Publication Date
PL375414A1 true PL375414A1 (pl) 2005-11-28

Family

ID=31720553

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03375414A PL375414A1 (pl) 2002-08-07 2003-07-28 Terapeutyczne połączenie inhibitorów kinazy erb Bi terapii przeciwnowotworowych

Country Status (17)

Country Link
US (2) US20040067942A1 (pl)
EP (1) EP1549320A1 (pl)
JP (1) JP2005538129A (pl)
CN (1) CN1674908A (pl)
AR (1) AR040792A1 (pl)
AU (1) AU2003249450A1 (pl)
BR (1) BR0313470A (pl)
CA (1) CA2494270A1 (pl)
IL (1) IL166423A0 (pl)
MX (1) MXPA05001430A (pl)
NO (1) NO20051170L (pl)
PA (1) PA8578001A1 (pl)
PE (1) PE20040990A1 (pl)
PL (1) PL375414A1 (pl)
RU (1) RU2005102836A (pl)
TW (1) TW200404532A (pl)
WO (1) WO2004014386A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US7695731B2 (en) 2004-03-22 2010-04-13 Cordis Corporation Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury
JP4823894B2 (ja) 2004-04-09 2011-11-24 中外製薬株式会社 新規水溶性プロドラッグ
ME01267B (me) 2004-05-06 2013-06-20 Warner Lambert Co 4-fenilaminokinazolin-6-ilamidi
WO2005117887A1 (en) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with gemcitabine and an egfr-inhibitor
CN1968706A (zh) 2004-06-03 2007-05-23 霍夫曼-拉罗奇有限公司 用顺铂和egfr－抑制剂治疗
EP1761264A1 (en) * 2004-06-03 2007-03-14 F.Hoffmann-La Roche Ag Treatment with irinotecan (cpt-11) and an egfr-inhibitor
CA2569139A1 (en) * 2004-06-04 2005-12-22 Smithkline Beecham (Cork) Limited Lapatinib with letrozole for use in a treatment of breast cancer
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
JP2009538317A (ja) * 2006-05-26 2009-11-05 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
RU2325199C2 (ru) * 2006-06-20 2008-05-27 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) Способ комбинированного лечения местно-распространенных форм рака шейки матки
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
KR20100102609A (ko) * 2007-11-12 2010-09-24 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법
JP2014514359A (ja) * 2011-05-06 2014-06-19 メリマック ファーマシューティカルズ インコーポレーティッド 抗ＥｒｂＢ３剤を含む併用治療において有毒な薬物相互作用を予防するための方法
WO2021178789A1 (en) * 2020-03-06 2021-09-10 Deciphera Pharmaceuticals, Llc Methods of using rebastinib in the treatment of different cancerous disorders
CN118576601A (zh) * 2020-10-23 2024-09-03 和记黄埔医药（上海）有限公司 一种药物组合产品在制备用于治疗结肠癌的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287223B1 (en) * 1997-04-11 2001-09-11 Liechty, Ii Victor Jay Dulling prevention for sharp cutting edge of blade-opening arrowhead blades when in a closed in-flight position
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells
US6281223B1 (en) * 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
RU2292904C2 (ru) * 2001-01-09 2007-02-10 Мерк Патент Гмбх Комбинированная терапия, использующая ингибиторы рецептора тирозинкиназы и ингибиторы ангиогенезиса

Also Published As

Publication number Publication date
MXPA05001430A (es) 2005-06-06
NO20051170L (no) 2005-05-06
IL166423A0 (en) 2006-01-15
PE20040990A1 (es) 2004-12-27
BR0313470A (pt) 2005-06-21
CN1674908A (zh) 2005-09-28
JP2005538129A (ja) 2005-12-15
PA8578001A1 (es) 2004-05-07
CA2494270A1 (en) 2004-02-19
AU2003249450A1 (en) 2004-02-25
EP1549320A1 (en) 2005-07-06
TW200404532A (en) 2004-04-01
AR040792A1 (es) 2005-04-20
US20040067942A1 (en) 2004-04-08
WO2004014386A1 (en) 2004-02-19
RU2005102836A (ru) 2005-08-10
US20060293323A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
IL166423A0 (en) Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies
EP1539129A4 (en) DOSAGE FORMS AND RELEVANT THERAPIES
PL375447A1 (pl) Inhibitory kinaz białkowych i ich zastosowania
PL403456A1 (pl) Pochodne 5-fenylotiazolu oraz ich zastosowanie jako inhibitorów kinazy Pi3
HRP20041029A2 (en) Therapeutic use of selcetive pde10 inhibitors
IL176233A0 (en) Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors
AU2003256410A8 (en) Combination therapy with p38 map kinase inhibitors and their pharmaceutical compositions
EP1501514A4 (en) PROTEIN-KINASE MODULATORS AND METHODS OF USE
AU2003303128A8 (en) Inhibitors and methods of use thereof
PH12012501372A1 (en) Proteasome inhibitors and methods of using the same
PL372620A1 (pl) Nowe kompozycje farmaceutyczne na bazie antycholinergików oraz inhibitorów kinazy p38
AU2003220437A1 (en) Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
ZA200600176B (en) Combination of SRC kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
AU2002247208A1 (en) Selective pde3b inhibitors and use of the same in therapy
PL369005A1 (pl) Kombinacje obejmujące inhibitory enzymu COX-2 i aspirynę
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
ZA200601293B (en) Proteasome inhibitors and methods of using the same
EG24845A (en) Pharmaceutical combinations of cox-2 inhibitors and opiates
AU2003257043A8 (en) Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors
AU2003251513A8 (en) Rsk inhibitors and therapeutic uses thereof
AU2003245627A8 (en) Kinases and phosphatases
PL369736A1 (pl) Nowe kompozycje leków na bazie antycholinergików oraz inhibitorów kinazy EGFR
ZA200501026B (en) Therapeutic combinations of erb B kinase inhibitors and antineoplastic therapies
EP1569928A4 (en) THERAPEUTIC COMPOUNDS AND METHOD
AU2003287427A8 (en) Kinases and phosphatases

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)